

BioSpect

the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.co

MrMed establishes physical presence in Guwahati

30 June 2026 | News

Strengthening access to critical care medicines across Northeast India



Chennai-based startup MrMed, a direct-to-patient platform for critical care and super-specialty medicines, has announced the establishment of its physical presence in Guwahati. The move strengthens MrMed's ability to serve patients across Northeast India, a region where access to high-value, tightly regulated medicines has historically been constrained by geography, limited pharmacy infrastructure, and the high cost of specialty therapies.

Guwahati represents a natural choice for MrMed. As the primary healthcare gateway for the Northeast, the city serves patients across Assam, Meghalaya, Manipur, Mizoram, Nagaland, Tripura, and Arunachal Pradesh, states where specialty pharmacy infrastructure remains sparse.

For patients managing conditions such as cancer, HIV, hepatitis, rare diseases, or transplant-related therapies, the absence of reliable local access has long meant either travelling to distant metros or risking treatment interruption, both outcomes that carry serious clinical and financial consequences.

MrMed's Guwahati presence, comprising a physical store on Motilal Nehru Road in Kamrup Metropolitan staffed by a three-person team (a store manager plus executives managing orders and hub operations), is designed to directly address this gap, enabling faster fulfilment, improved treatment continuity, and significantly more affordable access to critical medicines for patients across the region.

Looking ahead, MrMed is progressing with plans to expand its physical presence and cold-chain infrastructure across additional cities in India including Mumbai, Hyderabad and more, with a sustained focus on geographies where patients currently face the greatest barriers to accessing specialty medicines.

The company is also broadening its role within the healthcare ecosystem by entering allied super-specialty services, including home-based cancer care such as nurse-led infusions and pre- and post-chemotherapy support aimed at reducing hospital visits and improving continuity of care for patients on extended treatment cycles.